Belite Bio (BLTE) Q2 FY26 earnings call: guidance and Q&A

Earnings call· Jun 2026 (Q2 FY26)· Health Care· Aug 13, 2026

Source: earnings call transcript

Executive summary

Belite Bio Q2 FY26 — Tinlarebant NDA Accepted with Priority Review

Belite Bio achieved a significant milestone with the FDA's acceptance of the Tinlarebant NDA for Stargardt disease under Priority Review, targeting a February 2027 PDUFA date. The company is well-funded for commercialization and pipeline development, despite increased operating expenses driven by R&D milestones and pre-commercial preparations. Management is focused on the regulatory process while also advancing its pediatric and geographic atrophy programs.

Highlights

FDA accepted New Drug Application (NDA) for Tinlarebant with Priority Review, establishing a PDUFA date of February 12, 2027.
Cash, cash equivalents, and U.S. treasury bills totaled $780 million, providing a strong runway for commercialization and pipeline advancement.
Phase III DRAGON study results showed Tinlarebant treated subjects decreased qAF values by approximately 2% at month 25, compared to a 20% increase in the placebo group.

Concerns

GAAP net loss increased to $28.4 million in Q2 FY26 from $16.3 million in Q2 FY25.
R&D expenses increased to $18.2 million in Q2 FY26 from $11 million in Q2 FY25, primarily due to a confidential royalty payment.
SG&A expenses increased to $16.7 million in Q2 FY26 from $6.5 million in Q2 FY25, driven by team expansion and professional service fees.

Guidance & targets

Category	Target	Timeline	Confidence
Tinlarebant FDA Approval	February 12, 2027 PDUFA date high materiality	Q1 FY27	High
Tinlarebant European Filing	Sometime after FDA approval medium materiality	Post-FDA approval	Medium
Geographic Atrophy Interim Analysis	Sometime Q1 FY27, after February PDUFA medium materiality	Q1 FY27	Medium
Tinlarebant Japan Approval	Around 3 months after FDA approval medium materiality	Post-FDA approval	High

Risks & headwinds

Increased R&D expenses Q2 FY26

$18.2M in Q2 FY26 vs $11M in Q2 FY25 (GAAP)

Increased SG&A expenses Q2 FY26

$16.7M in Q2 FY26 vs $6.5M in Q2 FY25 (GAAP)

Confidentiality of royalty payment Q2 FY26

Amount not disclosed

Mitigation:Company stated Columbia asked for confidentiality.

Uncertainty of AdCom for Tinlarebant NDA During NDA review process (until Feb 2027)

No AdCom planned currently, but FDA could decide later

Mitigation:Company will update if FDA provides further details.

What to watch in Q3 FY26

Tinlarebant FDA Approval

February 2027

Current NDA accepted with Priority Review

Target Approval

Why it matters

Potential market entry for Stargardt disease, validating the company's lead asset.

We are very pleased to announce that the FDA has accepted our new drug application for Tinlarebant with priority review and establishing a PDUFA date of February 12, 2027.

Find out whether BLTE delivers this. Inve re-checks your case every morning.

Q&A highlights

What role will DRAGON II play in the U.S. filing, and what are the plans for pediatric development of Tinlarebant?

DRAGON II is primarily for the Japan PMDA and will not contribute to the U.S. NDA. A pediatric study (PIP) is being initiated in London for patients younger than 12 years old to inform regulatory processes.

“For the DRAGON 2, I think at this stage, it's still pretty much a Japan study for the PMDA. Right now, we don't think -- we don't believe that the DRAGON II will contribute to the NDA process. As for the pediatric study, we do have plans, and I'll let Hendrik shed more light on the details of that study.”

asked by Judah Frommer · answered by Yu-Hsin Lin

2 min read 5 chapters

Detailed narrative

Tinlarebant Regulatory Progress

The FDA accepted Belite Bio's New Drug Application for Tinlarebant for Stargardt disease with Priority Review, setting a PDUFA date of February 12, 2027. This acceptance reflects the strength and consistency of the clinical data. The company is now highly focused on the regulatory review process and pre-commercial preparations, engaging closely with medical and patient communities.

Clinical Data Presentations and Mechanism of Action

Belite Bio presented new secondary endpoint data from its Phase III DRAGON study at four medical conferences, including the American Society of Retina Specialists Annual Meeting. These presentations highlighted that subjects treated with Tinlarebant showed an approximate 2% decrease in quantitative autofluorescence (qAF) values at month 25 compared to baseline, while placebo subjects experienced an approximate 20% increase. This data reinforces Tinlarebant's mechanism of action in preventing or reducing toxic bisretinoid accumulation, a key driver of retinal degeneration in Stargardt disease.

Pipeline Expansion: Pediatric and Geographic Atrophy Programs

The company is initiating a pediatric study (PIP study) in London to investigate Tinlarebant in patients younger than 12 years old, which will serve as the basis for informing regulatory processes for this age group. Additionally, an interim analysis for the Geographic Atrophy (GA) trial is anticipated in the first quarter of 2027, likely after the Tinlarebant PDUFA date, as the company prioritizes its interactions with the FDA for Stargardt disease approval.

International Regulatory Strategy

Belite Bio's primary focus is on securing FDA approval for Tinlarebant. Following this, the company plans to pursue European filing to ensure consistent messaging and alignment with FDA outcomes. The Japan PMDA submission is proceeding in parallel with the FDA process, with approval expected approximately three months after FDA approval, leveraging the Sakigake designation.

Financial Position and Cash Runway

Belite Bio ended the second quarter of 2026 with a strong financial position, holding $780 million in cash, cash equivalents, and U.S. treasury bills. This substantial cash balance provides a runway to support the commercialization of Tinlarebant following potential regulatory approval and to continue advancing its broader pipeline programs.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.